Biogen BIIB LEQEMBI — Expense reflected within statements of income

Similar metrics at other companies

ASHIncome Loss From Equity Method Investments And Other Income Expense

$0—

ASHLife Sciences — Income Loss From Equity Method Investments And Other Income Expense

$0—

ADNTEquity income or loss

$2M-27.3%

PARRLogistics — Income (Loss) From Equity Method Investments, Operating

$2.45M+10.2%

NJRES — Income (Loss) from Equity Method Investments

$0—

LODEBioleum — Income Loss From Equity Method Investments

-$24K—

Questions, answered.

What is Biogen's LEQEMBI — expense reflected within statements of income?

Biogen (BIIB) reported LEQEMBI — expense reflected within statements of income of $84.7M in Q1 2026.

How has Biogen's LEQEMBI — expense reflected within statements of income changed year-over-year?

Biogen's LEQEMBI — expense reflected within statements of income decreased by 4.6% year-over-year, from $88.8M to $84.7M.

What is the long-term trend for Biogen's LEQEMBI — expense reflected within statements of income?

Over 3 years (2022 to 2025), Biogen's LEQEMBI — expense reflected within statements of income has grown at a 26.4% compound annual growth rate (CAGR), from $173.6M to $350.8M.

What does LEQEMBI — expense reflected within statements of income mean?

This metric represents the portion of collaborative development or operating expenses that is recognized directly on the company's consolidated statement of income. It reflects the specific accounting impact of the partnership's activities on the company's reported profitability. Investors use this to reconcile how collaborative activities translate into actual financial statement line items.